
Perceptive Advisors Life Sciences Investment Firm is a subsidiary of Perceptive Advisors, a leading investment firm that has been a significant player in the life sciences industry for over two decades.
Perceptive Advisors Life Sciences Investment Firm focuses on investing in innovative life sciences companies with the potential to transform human health.
With a strong track record of success, the firm has invested in numerous life sciences companies, including those in the biotechnology and pharmaceutical sectors.
Perceptive Advisors Life Sciences Investment Firm has a team of experienced investment professionals who have a deep understanding of the life sciences industry and a proven ability to identify and invest in promising companies.
Explore further: Investment Firm Specialising in Managing Risk
Investments
Perceptive Advisors has made 270 investments, with their latest being in Kardigan as part of their Series A on January 10, 2025.
Some of their notable investments include partnerships with Cooley, a law firm based in the United States, and LianBio, a company based in China.
Perceptive Advisors' investments span across different countries, with partnerships in the United States and China.
Curious to learn more? Check out: China Great Wall Asset Management
13D Filing: VBI Vaccines Inc
VBI Vaccines Inc made a 13D filing with the SEC, which means they own more than 5% of the company's outstanding shares.
On July 8, 2020, VBI Vaccines Inc acquired 1,511,111 shares of the company.
Take a look at this: Blackrock Realty Advisors Inc
Investments
Perceptive Advisors has a diverse portfolio of investments, with a focus on innovative healthcare companies. They invest in companies working on transformative ideas in the life sciences industry.
Perceptive Advisors has invested in over 270 companies, with a range of investment sizes from $15 million to $200 million. They seek to partner with strong management teams that have clear goals and a proven track record.
Some of the notable companies that Perceptive Advisors has invested in include Kindbody, Xontogeny, and Kodiak. These companies are working on innovative solutions in areas such as fertility care, medical devices, and biopharmaceuticals.
Perceptive Advisors has also invested in companies like VBI Vaccines, LYRA Therapeutics, and DNAnexus, which are developing vaccines, therapeutics, and medical technologies.
Curious to learn more? Check out: B Capital

Here are some of the companies that Perceptive Advisors has invested in:
- Kindbody: Offers gynecology, fertility, and family-building care in modern, tech-enabled clinics.
- Xontogeny: Collaborates with entrepreneurs, scientific founders, and first-time CEOs to drive the successful development of technologies.
- Kodiak: A biopharma company committed to researching, developing, and commercializing transformative therapeutics to treat age-related macular degeneration and diabetic eye diseases.
- VBI Vaccines: A biotechnology company developing a pipeline of vaccine and immunotherapeutic candidates to power the human immune system to prevent and fight diseases.
- LYRA Therapeutics: A clinical-stage company developing a new therapeutic approach to treat chronic ear, nose, and throat (ENT) diseases.
- DNAnexus: The world’s most secure, trusted cloud platform and global network for scientific collaboration and accelerated discovery.
Perceptive Advisors' investment strategy focuses on providing flexible capital solutions for companies in the life sciences industry. They seek to invest in companies that have strong management teams and clear goals.
Portfolio
Perceptive Advisors has a diverse portfolio that showcases their expertise in various areas.
Their experience in managing client assets spans over 15 years, with a significant portion of their clients being high-net-worth individuals.
Their investment philosophy is built on a long-term approach, focusing on creating sustainable wealth for their clients.
Life Sciences
Perceptive Advisors has been investing in public and private companies for over 18 years, providing support throughout their lifecycle.
They invest in companies working in various healthcare areas, including biotechnology and pharmaceuticals.
Perceptive Advisors' expertise spans across different stages of a company's growth, from crossover rounds to public follow-on financings.
Here are some of the specific areas they focus on:
- Biotechnology
- Pharmaceuticals
- Diagnostics
- Digital Health
- Medical Devices
Portfolio Exits

Perceptive Advisors has a track record of 114 portfolio exits, with their latest exit being a reverse merger on October 4, 2024.
Their portfolio exits include a mix of different types, such as reverse mergers and initial public offerings (IPOs). One notable exit was the IPO of Zenas BioPharma on September 13, 2024.
The valuation of these exits is not publicly disclosed, but we do know that they involve significant amounts of money. For example, the IPO of Zenas BioPharma was valued at a substantial amount.
Perceptive Advisors has also facilitated acquisitions, such as the acquisition of Cerevel Therapeutics by AbbVie on August 1, 2024. This acquisition was valued at a significant amount, but the exact figure is not disclosed.
Here's a summary of some of their notable portfolio exits:
These exits demonstrate Perceptive Advisors' ability to successfully exit their portfolio companies and achieve significant returns for their investors.
Fund History
Perceptive Advisors has a total of 12 funds, including Perceptive Xontogeny Venture Fund II.

The company has a significant presence in the venture capital space with funds like Perceptive Xontogeny Venture Fund II, which closed on May 12, 2021, with an amount of $515M.
One notable fund is Perceptive Credit Opportunities Fund III, which closed on November 16, 2020, with an impressive amount of $1,100M.
Another fund, Perceptive Credit Opportunities Offshore Fund III, closed on September 1, 2020, with an amount of $297.9M.
Here are some key details about Perceptive Advisors' funds:
The exact amount of Perceptive Credit Opportunities III SLP is not publicly available, but it's worth noting that the company has a significant presence in the credit opportunities space with multiple funds.
Partnerships
Perceptive Advisors has formed strategic partnerships to drive growth and innovation. Perceptive Advisors recently partnered with Cooley on June 6, 2024.
Perceptive Advisors has two strategic partners and customers. One of these partners is Cooley, a US-based business.
Perceptive Advisors' partnership with Cooley is a vendor partnership, established on June 17, 2024.
A different take: Schonfeld Strategic Advisors
Partners & Customers

Perceptive Advisors has formed strategic partnerships with various businesses. One of its notable partnerships is with Cooley, which was established on June 6, 2024.
Cooley is a US-based business partner of Perceptive Advisors.
Perceptive Advisors has also partnered with LianBio, a Chinese company, on August 11, 2020.
LianBio is a vendor partner of Perceptive Advisors, as listed on August 11, 2020.
Perceptive Advisors' partnerships with Cooley and LianBio demonstrate its ability to collaborate with businesses from different countries and industries.
Here are the details of Perceptive Advisors' partnerships:
Frequently Asked Questions
Is Perceptive Advisors a hedge fund?
Yes, Perceptive Advisors is a hedge fund that specializes in biotechnology stocks. It was founded in 1999 by Joseph Edelman to support progress in the life sciences industry.
Featured Images: pexels.com


